Instadose Pharma Corp.
INSD
$0.00
$0.000.00%
OTC PK
| 02/28/2022 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -94.80% | ||||
| Depreciation & Amortization | 0.31% | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -91.52% | ||||
| Operating Income | 91.52% | ||||
| Income Before Tax | 91.31% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 91.31% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 91.31% | ||||
| EBIT | 91.52% | ||||
| EBITDA | 94.80% | ||||
| EPS Basic | 91.83% | ||||
| Normalized Basic EPS | 91.54% | ||||
| EPS Diluted | 91.83% | ||||
| Normalized Diluted EPS | 91.54% | ||||
| Average Basic Shares Outstanding | 6.09% | ||||
| Average Diluted Shares Outstanding | 6.09% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||